Advertisement

Digestive Diseases and Sciences

, Volume 58, Issue 4, pp 1035–1041 | Cite as

Effect of Mosapride Combined with Esomeprazole Improves Esophageal Peristaltic Function in Patients with Gastroesophageal Reflux Disease: A Study Using High Resolution Manometry

  • Yu Kyung Cho
  • Myung-Gyu ChoiEmail author
  • Eun Young Park
  • Chul Hyun Lim
  • Jin Su Kim
  • Jae Myung Park
  • In Seok Lee
  • Sang Woo Kim
  • Kyu Yong Choi
Original Article

Abstract

Background

Whether addition of prokinetics to proton pump inhibitors improves esophageal peristalsis and symptoms in patients with gastroesophageal reflux disease (GERD) remains unknown.

Aim

We evaluated the effect of mosapride, a 5-HT4 agonist, and PPI cotherapy in patients with GERD on esophageal motility using high-resolution manometry (HRM).

Method

This study was designed as a double-blind, randomized, placebo-controlled trial. Patients with GERD were allocated to a group either taking 40 mg esomeprazole plus 30 mg mosapride or taking esomeprazole plus placebo. Symptom assessment and the HRM study were conducted before drug treatment and after 4 weeks.

Results

Of 50 patients enrolled, 24 in the mosapride group (49 years old, 15 males) and 19 in the placebo group (43 years old, nine males) completed the study. Approximately 79 % of the patients had normal peristaltic function. Treatment response was not different between the two groups (79 vs. 68 %). Mosapride cotherapy tended to yield better response in patients with dyspepsia than those without dyspepsia (92 vs. 67 %). Lower esophageal sphincter pressure didn’t change in both groups. Intrabolus pressure decreased in the mosapride group (3.4 ± 3.5 mmHg to 1.4 ± 4.1 mmHg, P < 0.05). Distal esophageal amplitude increased in the mosapride group and not in the placebo group (81 ± 34 to 89 ± 29 mmHg vs. 82 ± 32 to 83 ± 31 mmHg).

Conclusion

Adding mosapride on esomeprazole improved esophageal contractability and lowered intrabolus pressure in patients with GERD. Mosapride and esomeprazole cotherapy tended to yield better response in patients with concomitant dyspepsia.

Keywords

Gastroesophageal reflux Mosapride Esophageal motility 

Notes

Acknowledgments

This work was supported by a research grant from Daewoong Pharmaceuticals Co, Ltd.

Conflict of interest

None.

References

  1. 1.
    Fock KM, Talley NJ, Fass R, et al. Asia-Pacific consensus on the management of gastroesophageal reflux disease: update. J Gastroenterol Hepatol. 2008;23:8–22.PubMedCrossRefGoogle Scholar
  2. 2.
    Cucchiara S, Staiano A, Boccieri A, et al. Effects of cisapride on parameters of oesophageal motility and on the prolonged intraoesophageal pH test in infants with gastro-oesophageal reflux disease. Gut. 1990;31:21–25.PubMedCrossRefGoogle Scholar
  3. 3.
    Goldin GF, Marcinkiewicz M, Zbroch T, Bityutskiy LP, McCallum RW, Sarosiek J. Esophagoprotective potential of cisapride. An additional benefit for gastroesophageal reflux disease. Dig Dis Sci. 1997;42:1362–1369.PubMedCrossRefGoogle Scholar
  4. 4.
    Ruth M, Finizia C, Cange L, Lundell L. The effect of mosapride on oesophageal motor function and acid reflux in patients with gastro-oesophageal reflux disease. Eur J Gastroenterol Hepatol. 2003;15:1115–1121.PubMedCrossRefGoogle Scholar
  5. 5.
    Cho YK, Choi MG, Han HW, et al. The effect of mosapride on esophageal motility and bolus transit in asymptomatic volunteers. J Clin Gastroenterol. 2006;40:286–292.PubMedCrossRefGoogle Scholar
  6. 6.
    Koshino K, Adachi K, Furuta K, et al. Effects of mosapride on esophageal functions and gastroesophageal reflux. J Gastroenterol Hepatol. 2010;25:1066–1071.PubMedCrossRefGoogle Scholar
  7. 7.
    Futagami S, Iwakiri K, Shindo T, et al. The prokinetic effect of mosapride citrate combined with omeprazole therapy improves clinical symptoms and gastric emptying in PPI-resistant NERD patients with delayed gastric emptying. J Gastroenterol. 2010;45:413–421.PubMedCrossRefGoogle Scholar
  8. 8.
    Miwa H, Inoue K, Ashida K, et al. Randomised clinical trial: efficacy of the addition of a prokinetic, mosapride citrate, to omeprazole in the treatment of patients with non-erosive reflux disease—a double-blind, placebo-controlled study. Aliment Pharmacol Ther. 2011;33:323–332.PubMedCrossRefGoogle Scholar
  9. 9.
    Chen CL, Yi CH. Utility of esophageal impedance in identifying dysmotility in patients with erosive esophagitis. Dis Esophagus. 2008;21:539–543.PubMedCrossRefGoogle Scholar
  10. 10.
    Clouse RE, Staiano A, Alrakawi A, Haroian L. Application of topographical methods to clinical esophageal manometry. Am J Gastroenterol. 2000;95:2720–2730.PubMedCrossRefGoogle Scholar
  11. 11.
    Murray JA, Clouse RE, Conklin JL. Components of the standard oesophageal manometry. Neurogastroenterol Motil. 2003;15:591–606.PubMedCrossRefGoogle Scholar
  12. 12.
    Ghosh SK, Janiak P, Schwizer W, Hebbard GS, Brasseur JG. Physiology of the esophageal pressure transition zone: separate contraction waves above and below. Am J Physiol Gastrointest Liver Physiol. 2006;290:G568–G576.PubMedCrossRefGoogle Scholar
  13. 13.
    Fox M, Menne D, Stutz B, Fried M, Schwizer W. The effects of tegaserod on oesophageal function and bolus transport in healthy volunteers: studies using concurrent high-resolution manometry and videofluoroscopy. Aliment Pharmacol Ther. 2006;24:1017–1027.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 2012

Authors and Affiliations

  • Yu Kyung Cho
    • 1
  • Myung-Gyu Choi
    • 1
    Email author
  • Eun Young Park
    • 1
  • Chul Hyun Lim
    • 1
  • Jin Su Kim
    • 1
  • Jae Myung Park
    • 1
  • In Seok Lee
    • 1
  • Sang Woo Kim
    • 1
  • Kyu Yong Choi
    • 1
  1. 1.Division of Gastroenterology, Department of Internal Medicine, College of Medicine, Seoul St. Mary’s HospitalThe Catholic University of KoreaSeoulKorea

Personalised recommendations